Editors' ChoiceCancer

A one-two punch for CML

See allHide authors and affiliations

Sci. Signal.  04 Aug 2015:
Vol. 8, Issue 388, pp. ec218
DOI: 10.1126/scisignal.aad1316

Chronic myelogenous leukemia (CML) is classically associated with the pathogenic BCR-ABL1 translocation, which can be targeted by treatment with imatinib and other tyrosine kinase inhibitors. Unfortunately, these treatments do not eradicate leukemia stem cells, and many patients eventually relapse. Riether et al. showed that treatment-induced resistance and increase in CD70 abundance, which was a consequence of an increase in activity of the Wnt pathway. In addition, inhibiting the activity of CD70 prevented the development of resistant cells, suggesting that this may be helpful for treating CML patients.

C. Riether, C. M. Schürch, C. Flury, M. Hinterbrandner, L. Drück, A.-L. Huguenin, G. M. Baerlocher, R. Radpour, A. F. Ochsenbein, Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci. Transl. Med. 7, 298ra119 (2015). [Abstract]